Thymosin‑alpha‑1 is a synthetic 28‑amino‑acid peptide that can boost various parts of the immune system, like T‑cells and antibodies, and helps control inflammation. It’s been used as an add‑on treatment for infections, immune problems, and cancers, and early trials showed better survival after certain stem‑cell transplants. While the data are promising, the abstract doesn’t give dosing or safety details, so it’s more of a proof‑of‑concept for immune support rather than a ready‑to‑use protocol.

Thymosin α1 (Tα1), a thymosin-related 28-mer synthetic amino-terminal acetylated peptide, has gained increasing interest in recent years, due to its pleiotropy. The peptide has been used worldwide as an adjuvant or immunotherapeutic agent to treat disparate human diseases, including viral infections, immunodeficiencies, and malignancies. The peptide can enhance T cell, dendritic cell (DC), and antibody responses, modulate cytokine and chemokine production, and block steroid-induced apoptosis of thymocytes. Its central role in modulating DC function and activating multiple signaling pathways that contribute to different functions may offer a plausible explanation for its pleiotropic action. Additionally, the ability of Tα1 to activate the indoleamine 2,3-dioxygenase enzyme-which confers immune tolerance during transplantation and restrains the vicious circle of chronic inflammation-has been a turning point, suggesting a potential, specific function in immunity. Accordingly, Tα1 has recently been shown to promote immune reconstitution and improve survival of recipients of HLA-matched sibling T cell-depleted stem cell transplants in a phase I/II clinical trial. Thus, Tα1 continues to live up to its promises.